Cervical Cancer Vaccines Market, By Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Siz

Cervical Cancer Vaccines Market, By Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast, 2022 - 2028

Cervical cancer is a common type of cancer occurring in women worldwide. A major cause of cervical cancer is infection by human papillomavirus (HPV), which is found in 99% cervical cancer. Human papillomavirus is sexually transmitted. Around 100 types of HPV have been identified to date, of which types 16 and 18 are believed to be responsible for more than 70% of cervical cancers. Cervarix and Gardasil are type of vaccines used for the treatment of cervical cancer.
Market Dynamics
Increasing prevalence of cervical cancer worldwide is expected to boost the cervical cancer vaccines market growth. According to the World Health Organization (WHO), 2021, cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases and representing 6.6% of all female cancers worldwide and around 85% of deaths occur due to cervical cancer in developing countries.
However, lack of awareness amongst the people in the low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the cervical cancer vaccines market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer’s (IARC) report of 2013, cervical cancer is most notable in low-income countries of sub-Saharan Africa.
Key features of the study:
This report provides in-depth analysis of the global cervical cancer vaccines market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the cervical cancer vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, GlaxoSmithKline plc. and Merck & Co. Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The cervical cancer vaccines market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for immune repertoire sequencing market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Cervical Cancer Vaccines Market , By Product Type:
Gardasil
Gardasil 9
Cervarix
Global Cervical Cancer Vaccines Market, By Distribution Channel:
Hospitals
Clinics
Government Entities
Global Cervical Cancer Vaccines Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type:
Gardasil
Gardasil 9
Cervarix
By Distribution Channel:
Hospitals
Clinics
Government Entities
Company Profiles
GlaxoSmithKline plc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co. Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
“*” marked represents similar segmentation in other categories in the respective section.